_:nde92fe4eeb5e4230b47deab2fd630bbbxb5
<http://schema.org/position>
<https://www.cancertherapyadvisor.com/home/cancer-topics/lymphoma/fda-expands-tisagenlecleucel-indication-to-include-relapsed-refractory-b-cell-lymphomas/>